title: Treatment and prognostic factors in primary peritoneal carcinoma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO).
abstract: BACKGROUND
  In this study, we aimed to evaluate the clinicopathological characteristics and prognosis of patients with primary peritoneal carcinoma (PPC), and the effectiveness and toxicity of first-line platinum/taxane combination therapy.
  
  
  METHODS
  We retrospectively evaluated 79 patients with PPC, who were treated and followed up between December 2001 and August 2012 at 10 medical oncology clinics.
  
  
  RESULTS
  All patients were female, with a median age of 63 years (range 34-79 years). Histopathological diagnoses included primary peritoneal serous carcinoma (PPSC) (n = 69) and mixed epithelial carcinoma of the peritoneum (MEC) (n = 10). Patients received first-line treatment with carboplatin/paclitaxel (n = 67) or cisplatin/paclitaxel (n = 12) combination therapy. Overall response rate, median progression-free survival, and median survival time in the paclitaxel/carboplatin group and the paclitaxel/cisplatin group were 74.6 vs. 75%, 15.6 vs. 37.8 months, and 41 vs. 70.3 months, respectively. In multivariate analysis, favorable prognostic factors were: ECOG performance status 0 (p < 0.001) and optimal cytoreduction (p = 0.03).
  
  
  CONCLUSIONS
  PPC is a rare, heterogeneous disease. ECOG performance status and optimal cytoreduction are important prognostic factors regarding survival rates. Platinum/taxane combination therapy is an effective and tolerable regimen in this patient group.
authors.affiliation: Division of Medical Oncology, Department of Internal Medicine, Ataturk University Faculty of Medicine, Erzurum, Turkey.
authors.forename: Olcun U
authors.initials: OU
authors.lastname: Unal
authors.forename: Ilhan
authors.initials: I
authors.lastname: Oztop
authors.forename: Ozan
authors.initials: O
authors.lastname: Yazici
authors.forename: Tahsin
authors.initials: T
authors.lastname: Ozatli
authors.forename: Ali
authors.initials: A
authors.lastname: Inal
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Günaydın
authors.forename: Suleyman
authors.initials: S
authors.lastname: Alici
authors.forename: Umut
authors.initials: U
authors.lastname: Demirci
authors.forename: Havva Y
authors.initials: HY
authors.lastname: Cinkir
authors.forename: Bilge
authors.initials: B
authors.lastname: Aktas
authors.forename: Kubra
authors.initials: K
authors.lastname: Aslan
authors.forename: Dogan
authors.initials: D
authors.lastname: Uncu
authors.forename: Ahmet U
authors.initials: AU
authors.lastname: Yilmaz
authors.forename: Berna
authors.initials: B
authors.lastname: Oksuzoglu
authors.forename: Suleyman
authors.initials: S
authors.lastname: Buyukberber
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D016190:Carboplatin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D010534:Peritoneal Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D015995:Prevalence; D011379:Prognosis; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome; D014421:Turkey / Q000453:epidemiology
chemical_list: D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin